Phio Pharmaceuticals Corp.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Operating income | -$9.2M | -$7.4M | -$10.8M | -$11.5M | -$13.5M |
| Operating expenses | $9.2M | $7.4M | $10.8M | $11.5M | $13.5M |
| Cash from operations | -$8.0M | -$7.1M | -$10.7M | -$12.1M | -$11.9M |
| Capital expenditure | $12,000 | $1,000 | $5,000 | $121,000 | $51,000 |
| Free cash flow | -$8.0M | -$7.1M | -$10.8M | -$12.2M | -$11.9M |
| Impairments | — | $0 | $126,000 | $0 | $0 |
| Total assets | $21.5M | $5.7M | $9.4M | $12.8M | $25.2M |
| Total liabilities | $1.3M | $1.0M | $1.6M | $2.0M | $3.2M |
Shares outstanding 11.6M · Free float 64.0%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.